🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow https://t.co/xzOaFIu06e @RheumNow https://t.co/tmr4USETJ3

• https://bit.ly/301hRiN

#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx

• Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…

CH COVID 19 Poster Review Abst 0196 Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm - Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome #ACR21 @RheumNow https://t.co/hX7bBtrIzT

Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK

• Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…

Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting. https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn

• https://bit.ly/3qj7KBa

#ACR21 L17: Heterologous vs Homologous Booster vax ▶️RTX non-responders to mRNA: Randomized to mRNA 3rd dose vs AZ vax ⭐️Majority of pts develop immune response (humoral and/or cellular) after 3rd dose, no statistical diff b/w groups @Rheumnow https://t.co/cuM9LcEr4u https://t.co/cmNBNSIoOl

• https://bit.ly/3mUsMUp

What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVaccination. With 3rd vaccine dose up to 94% can have immune response! Pts need their 3rd vaccination @RheumNow #ACR21 #ACRBest abstL17 https://t.co/0GHOuoqPKQ

👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,⬆️hosp stay,⬆️severity, persistent viremia,⬆️deaths) 👉study adding booster (AZ or mRNA) overcomes this, enhancing humoral and cellular response #ACR21 @rheumnow Abst#L17 https://t.co/yuX1TT6ZBF

Very interesting talk Abst L16 Singh & colleagues found that patients with rheumatic diseases are at increased risk for breakthrough infxn - Recent drug exposure and certain medication type can influence outcomes - Findings support need for 3rd dose in RD pts #ACR21 @RheumNow https://t.co/vU6ZNIEWbc

USA EMR (N3C) Data on 577,335 Rheum Pts w/18,164 #COVID19 breakthrough infx (BTI) 👉91% vax'd 👉3.1% w/BTI 👉86% were vax'd May 2021 or earlier 👉More BTI w/Pfizer 👉BTI higher in inflamm myositis, RA 👉Drugs assc w/BTI: biologics, mult DMARDs #ACR21 @rheumnow Abst#L16 #ACRbest https://t.co/Eu77vAAk3N